ArticleFrontiers in pharmacology2025
Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case report of drug-drug interaction between voriconazole and simnotrelvir/ritonavir.Frontiers in antibiotics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The concomitant use of nirmatrelvir/ritonavir and voriconazole is generally contraindicated in clinical practice because of drug‒drug interactions (DDIs). However, emerging clinical data suggest that this DDI is complicated and that the concomitant use of these two drugs may be feasible. Methods: This was a multicenter retrospective study. Hospitalized patients who were diagnosed with COVID-19 in 2023 and who received concomitant nirmatrelvir-ritonavir and voriconazole were retrospectively included according to preset criteria. Personal information, medication records and voriconazole plasma levels were obtained from the hospital information system. The voriconazole concentrations were analyzed. Results: A total of 13 hospitalized patients with COVID-19 and 16 voriconazole trough concentrations were included from 4 centers. Half of the patients (8 patients, 50.0%) had voriconazole plasma concentrations within the therapeutic range. The remaining 8 cases (50.0%) fell outside the therapeutic range, including 1 case (12.5%) with subtherapeutic levels and 7 cases (87.5%) with supratherapeutic concentrations. Conclusion: The concomitant use of nirmatrelvir/ritonavir and voriconazole might be feasible, but the dosing of voriconazole needs further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.